Search Results

You are looking at 51 - 60 of 83 items for :

  • Refine by Access: All content x
Clear All
Open access

Hugo R Ramos, Andreas L Birkenfeld, and Adolfo J de Bold

(125) ; an observation that seems to depend on the amount of weight loss (126, 127) . Experimental data further suggests that the incretin glucagon like peptide 1 (GLP1) might be of relevance in the regulation of NP secretion. The GLP1 receptor agonist

Open access

Lin Ji, Huan-Tong Wu, Xiao-Yan Qin, and Rongfeng Lan

, Cpe KO Hyperproinsulinemia, β-cell stress Insulin, IAPP Naggert et al . 1995 , Marzban et al . 2005 Obesity Cpe fat / fat , Cpe KO Defects in energy balance regulation, satiety and nutrient partitioning CCK, neurotensin, GLP-1

Open access

Hong Wang, Jie Cao, Jian-bin Su, Xue-qin Wang, Dong-mei Zhang, and Xiao-hua Wang

alone, insulin treatments, insulin-secretagogues, pioglitazone, α-glucosidase inhibitors (AGIs), glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase 4 inhibitors (DPP-4Is). The BMI was calculated as the ratio of the weight (kg

Open access

Caishun Zhang, Junhua Yuan, Qian Lin, Manwen Li, Liuxin Wang, Rui Wang, Xi Chen, Zhengyao Jiang, Kun Zhu, Xiaoli Chang, Bin Wang, and Jing Dong

including PYY ( 17 ), leptin ( 18 ) and glucagon-like peptide-1 (GLP-1) ( 19 ) are involved in the control of food intake in the LPBN. Besides, our recent research showed that administration of anorexia peptide nesfatin-1 in rats’ LPBN could modulate food

Open access

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ, and Albert Beckers

, dipeptiyl peptidase-4 (DPP-4) inhibitors, a sulfonylurea and GLP-1 agonists. HbA1c was eventually brought down to <7% with the addition of insulin glargine. With chronic treatment using pasireotide LAR 40 mg/month, IGF-1 levels continually trended downwards

Open access

Julia Modesto Vicente, Junia Carolina Santos-Silva, Caio Jordão Teixeira, Dailson Nogueira de Souza, Jean Franciesco Vettorazzi, Fabiola Sales Furtuoso, Isabel Gouveia Adabo, Fabio Takeo Sato, Marco Aurélio Ramirez Vinolo, Everardo Magalhães Carneiro, Silvana Bordin, and Gabriel Forato Anhê

both neurotransmitters released during the cephalic phase of insulin release or incretins such as glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP) released by enteroendocrine cells in response to food transit ( 26 ). Human islets are

Open access

Anna C Simcocks, Kayte A Jenkin, Lannie O’Keefe, Chrishan S Samuel, Michael L Mathai, Andrew J McAinch, and Deanne H Hryciw

), adiponectin (AdipoGen, Liestal, Switzerland), glucagon-like peptide 1 (GLP-1), ghrelin, leptin (Bioplex hormone immunoassay; Bio-Rad Laboratories), erythropoietin (EPO), growth regulated α protein/keratinocyte chemoattractant (GROC/KC), interferon gamma (IFN

Open access

Eva O Melin, Jonatan Dereke, Maria Thunander, and Magnus Hillman

detection, to check the pharmacological response during therapeutic intervention, or that can be used as treatment targets ( 2 , 6 , 18 ). In previous research it has been shown that glucagon-like peptide 1 (GLP-1) analog therapy directly modulates innate

Open access

Maximilian Bielohuby, Martin Bidlingmaier, and Uwe Schwahn

.g. active GLP-1). Furthermore, it is important to check if further ‘additives’ are required to stabilize the analyte. One example for an analyte requiring a specific sampling protocol is acylated ghrelin, because here, acidification of the sample through

Open access

Melinda Kertész, Szilárd Kun, Eszter Sélley, Zsuzsanna Nagy, Tamás Kőszegi, and István Wittmann

decreasing insulin resistance (e.g. sodium-glucose cotransporter-2 inhibitors or GLP-1 receptor agonists) on the T3. There are some other important data related to the T3 level and T3/T4 ratio in obese patients ( 32 ). After 6 months of gastric banding of